Intensity Therapeutics, Inc.
INTS
$1.94
$0.000.00%
| Weiss Ratings | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.83% | |||
| 30-Day Total Return | -14.16% | |||
| 60-Day Total Return | -25.38% | |||
| 90-Day Total Return | -30.40% | |||
| Year to Date Total Return | 10.86% | |||
| 1-Year Total Return | -57.46% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -63.22% | |||
| 52-Week Low % Change | 29.33% | |||
| Price | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.28 | |||
| 52-Week Low Price | $1.50 | |||
| 52-Week Low Price (Date) | Jan 02, 2025 | |||
| 52-Week High Price (Date) | May 17, 2024 | |||
| Valuation | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 29.45M | |||
| Enterprise Value | 27.00M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.39 | |||
| Earnings Per Share Growth | -37.22% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 10.05 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.94 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -1.63 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 14.40M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 203 221 7381 | |||
| Address | 1 Enterprise Drive Shelton, CT 06484-4779 | |||
| Website | www.intensitytherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -93.90% | |||
| Return on Equity | -- | |||
| Income Statement | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -16.59M | |||
| Net Income (TTM) | -16.27M | |||
| Net Income Avl. to Common (TTM) | -16.27M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -0.28% | |||
| EPS Diluted (TTM) | -1.39 | |||
| EPS Diluted Growth (Q YOY) | -91.84% | |||
| Balance Sheet | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.59M | |||
| Cash Per Share (Q) | $0.18 | |||
| Total Current Assets (Q) | 3.36M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.92M | |||
| Current Ratio (Q) | 1.916 | |||
| Book Value Per Share (Q) | $0.19 | |||
| Total Assets (Q) | 4.78M | |||
| Total Current Liabilities (Q) | 1.76M | |||
| Total Debt (Q) | 138.00K | |||
| Total Liabilities (Q) | 1.87M | |||
| Total Common Equity (Q) | 2.92M | |||
| Cash Flow | INTS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 6.35M | |||
| Cash from Financing (TTM) | 2.90M | |||
| Net Change in Cash (TTM) | -5.97M | |||
| Levered Free Cash Flow (TTM) | -14.15M | |||
| Cash from Operations (TTM) | -15.22M | |||
